Publications by authors named "Michael A Reilly"

Claim this Profile
P
Perspective on high-throughput bioanalysis to support assays in early drug discovery.
Brandon G Santiago, Stephen H Eisennagel, Gregory E Peckham, Amanda M Liebhardt, Chad L Alburn, Michael A Reilly

Bioanalysis· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding Pharmacokinetic Disconnect in Preclinical Species for 4-Aminoquinolines: Consequences of Low Permeability and High P-glycoprotein Efflux Ratio on Rat and Dog Oral Pharmacokinetics.
Mukesh K Mahajan, Elizabeth J Rivera, Helen H Sun, Rakesh Nagilla, Michael P DeMartino, Michael A Reilly

J Pharm Sci· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.
Pamela A Haile, Linda N Casillas, Michael J Bury, John F Mehlmann, Robert Singhaus, Michael A Reilly

ACS Med Chem Lett· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2.
Alina Mares, Afjal H Miah, Ian E D Smith, Mark Rackham, Aditya R Thawani, Michael A Reilly

Commun Biol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[]thiazol-5-ylamino)-6-(-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases.
Pamela A Haile, Linda N Casillas, Bartholomew J Votta, Gren Z Wang, Adam K Charnley, Michael A Reilly

J Med Chem· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Design of amidobenzimidazole STING receptor agonists with systemic activity.
Joshi M Ramanjulu, G Scott Pesiridis, Jingsong Yang, Nestor Concha, Robert Singhaus, Michael A Reilly

Nature· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer.
Philip A Harris, Jill M Marinis, John D Lich, Scott B Berger, Anirudh Chirala, Michael A Reilly

ACS Med Chem Lett· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of RIP1 Kinase Small-Molecule Inhibitors in Studying Necroptosis.
Allison M Beal, John Bertin, Michael A Reilly

Methods Mol Biol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase.
Philip A Harris, Nicolas Faucher, Nicolas George, Patrick M Eidam, Bryan W King, Michael A Reilly

J Med Chem· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of amidobenzimidazole STING receptor agonists with systemic activity.
Joshi M Ramanjulu, G Scott Pesiridis, Jingsong Yang, Nestor Concha, Robert Singhaus, Michael A Reilly

Nature· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.
Pamela A Haile, Linda N Casillas, Michael J Bury, John F Mehlmann, Robert Singhaus, Michael A Reilly

ACS Med Chem Lett· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.
Philip A Harris, Scott B Berger, Jae U Jeong, Rakesh Nagilla, Deepak Bandyopadhyay, Michael A Reilly

J Med Chem· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase.
Pamela A Haile, Bartholomew J Votta, Robert W Marquis, Michael J Bury, John F Mehlmann, Michael A Reilly

J Med Chem· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse.
Jonathan D Best, David W Smith, Michael A Reilly, Ruth O'Donnell, Huw D Lewis

J Pharmacol Exp Ther· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis